Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.45 |
| ▸ | ERBB4 | Q15303 | 9/20 | 0.45 |
| ▸ | JAK3 | P52333 | 5/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831990 | 0.84 | ERBB2 (0.57) | EGFRERBB2ERBB4JAK3EPHA2 | |
| SCHEMBL4466584 | 0.80 | EGFR (0.42) | EGFRERBB2ERBB4JAK3EPHA2 | |
| SCHEMBL4455172 | 0.74 | ERBB2 (0.58) | EGFRERBB2ERBB4JAK3EPHA2 | |
| SCHEMBL4462111 | 0.72 | ERBB2 (0.65) | EGFRERBB2EPHA2KDR | |
| SCHEMBL4476615 | 0.72 | ERBB2 (0.62) | EGFRERBB2EPHA2KDR | |
| SCHEMBL4475534 | 0.71 | ERBB2 (0.56) | EGFRERBB2ERBB4JAK3EPHA2 | |
| SCHEMBL4471436 | 0.71 | ERBB2 (0.59) | EGFRERBB2EPHA2KDR | |
| SCHEMBL4463707 | 0.71 | ERBB2 (0.60) | EGFRERBB2EPHA2KDR | |
| SCHEMBL4465922 | 0.70 | ERBB2 (0.73) | EGFRERBB2EPHA2KDR | |
| SCHEMBL4471115 | 0.70 | ERBB2 (0.72) | EGFRERBB2EPHA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNY | EGFR 166/4885ERBB2 1183/4885ERBB4 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.